PE20130253A1 - Factor viia conjugado para coagulacion de la sangre - Google Patents
Factor viia conjugado para coagulacion de la sangreInfo
- Publication number
- PE20130253A1 PE20130253A1 PE2012002103A PE2012002103A PE20130253A1 PE 20130253 A1 PE20130253 A1 PE 20130253A1 PE 2012002103 A PE2012002103 A PE 2012002103A PE 2012002103 A PE2012002103 A PE 2012002103A PE 20130253 A1 PE20130253 A1 PE 20130253A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- conjugated
- link
- fviia
- refers
- Prior art date
Links
- 230000023555 blood coagulation Effects 0.000 title 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 238000007259 addition reaction Methods 0.000 abstract 2
- 229940012414 factor viia Drugs 0.000 abstract 2
- 150000007944 thiolates Chemical class 0.000 abstract 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UN POLIMERO BIOCOMPATIBLE CONJUGADO A FACTOR DE COAGULACION VIIa (FVIIa) DE FORMULA (I), DONDE R1 ES UN SUSTITUYENTE QUE ES UN ENLACE DIRECTO, UN GRUPO ALQUILENO C1-10, UN GRUPO ARILO TAL COMO FENILO, BENZOILO Y NAFTILO; UN GRUPO HETEROARILO TAL COMO PIRIDINA, OXAZOL, PURINA, PIRAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE: a) REDUCCION DE UN ENLACE DISULFURO NATIVO ENTRE DOS RESIDUOS DE CISTEINA EN FVIIa PARA GENERAR DOS GRUPOS TIOL LIBRES; b) UNA PRIMERA REACCION DE ADICION DE TIOLATO ENTRE UN REACTIVO DE CONJUGACION (FORMULA II) QUE COMPRENDE UN DOBLE ENLACE CONJUGADO Y UN GRUPO SALIENTE; c) ELIMINACION DE UN GRUPO SALIENTE, QUE GENERA UN ENLACE DOBLE CONJUGADO; Y d) UNA SEGUNDA REACCION DE ADICION DE TIOLATO, QUE FORMA UNA CONEXION 3-CARBONO ENTRE LOS DOS ATOMOS DE AZUFRE. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1007356.7A GB201007356D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIIa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130253A1 true PE20130253A1 (es) | 2013-03-16 |
Family
ID=42289986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002103A PE20130253A1 (es) | 2010-04-30 | 2011-04-28 | Factor viia conjugado para coagulacion de la sangre |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9309507B2 (es) |
| EP (1) | EP2563403B1 (es) |
| JP (2) | JP2013525415A (es) |
| KR (1) | KR20130055620A (es) |
| CN (1) | CN102971013B (es) |
| AP (1) | AP2012006574A0 (es) |
| AU (1) | AU2011247148B2 (es) |
| CA (1) | CA2796870A1 (es) |
| CL (1) | CL2012003038A1 (es) |
| CO (1) | CO6660500A2 (es) |
| CR (1) | CR20120580A (es) |
| DK (1) | DK2563403T3 (es) |
| EA (1) | EA201290941A1 (es) |
| EC (1) | ECSP12012315A (es) |
| ES (1) | ES2503570T3 (es) |
| GB (2) | GB201007356D0 (es) |
| IL (1) | IL222565A (es) |
| MX (1) | MX2012012684A (es) |
| MY (1) | MY160510A (es) |
| NI (1) | NI201200161A (es) |
| NZ (1) | NZ603938A (es) |
| PE (1) | PE20130253A1 (es) |
| PH (1) | PH12012502149A1 (es) |
| PL (1) | PL2563403T3 (es) |
| RU (1) | RU2012144554A (es) |
| SG (1) | SG184573A1 (es) |
| WO (1) | WO2011135308A1 (es) |
| ZA (1) | ZA201208988B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| RU2595442C2 (ru) | 2009-07-27 | 2016-08-27 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| SG178051A1 (en) | 2009-07-27 | 2012-03-29 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| MY190257A (en) * | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| WO2014210546A1 (en) | 2013-06-27 | 2014-12-31 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| CA2397347C (en) | 2000-02-11 | 2011-07-12 | Maxygen Aps | Factor vii or viia-like molecules |
| US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
| AU2002249096B2 (en) | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
| DK1549341T3 (da) | 2002-05-01 | 2009-07-06 | Bayer Schering Pharma Ag | Mod vævsfaktor rettede antistoffer som antikoagulanter |
| DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| DK1517710T3 (da) * | 2002-06-21 | 2011-07-18 | Novo Nordisk Healthcare Ag | Pegylerede faktor VII-glycoformer |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US7432330B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| HUE058897T2 (hu) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polimer VIII-as faktor egység konjugátumok |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| ES2390082T5 (es) | 2004-06-30 | 2018-01-19 | Nektar Therapeutics | Conjugados de resto de Factor IX y polímeros |
| JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｆｖｉｉの抱合体 |
| ES2821832T3 (es) | 2004-11-12 | 2021-04-27 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| NZ572050A (en) | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| EP2118150B1 (en) | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
| RU2571931C2 (ru) | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| WO2009047500A1 (en) | 2007-10-09 | 2009-04-16 | Polytherics Limited | Novel conjugated proteins and peptides |
| WO2009130602A2 (en) * | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
| DK2326349T3 (en) * | 2008-07-21 | 2015-05-26 | Polytherics Ltd | Novel Reagents and Methods for Conjugation of Biological Molecules |
| EP2334336A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033223A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
| JP4966434B2 (ja) | 2008-10-15 | 2012-07-04 | バクスター・インターナショナル・インコーポレイテッド | 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 |
| SMT201800486T1 (it) | 2008-10-17 | 2018-11-09 | Baxalta Inc | Fattori sanguigni modificati comprendenti un grado basso di polimero solubile in acqua |
| JP2012508172A (ja) | 2008-11-03 | 2012-04-05 | バイエル・ヘルスケア・エルエルシー | 血友病の治療方法 |
| GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| CA2748662A1 (en) | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
| GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
| WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| PT2536399T (pt) | 2010-02-21 | 2020-02-06 | Bayer Healthcare Llc | Método para ativação e conjugação de biomoléculas |
-
2010
- 2010-04-30 GB GBGB1007356.7A patent/GB201007356D0/en not_active Ceased
-
2011
- 2011-04-28 RU RU2012144554/15A patent/RU2012144554A/ru not_active Application Discontinuation
- 2011-04-28 EA EA201290941A patent/EA201290941A1/ru unknown
- 2011-04-28 MX MX2012012684A patent/MX2012012684A/es not_active Application Discontinuation
- 2011-04-28 SG SG2012076790A patent/SG184573A1/en unknown
- 2011-04-28 AU AU2011247148A patent/AU2011247148B2/en not_active Ceased
- 2011-04-28 PL PL11719041T patent/PL2563403T3/pl unknown
- 2011-04-28 US US13/643,504 patent/US9309507B2/en not_active Expired - Fee Related
- 2011-04-28 CN CN201180021895.1A patent/CN102971013B/zh not_active Expired - Fee Related
- 2011-04-28 ES ES11719041.3T patent/ES2503570T3/es active Active
- 2011-04-28 DK DK11719041.3T patent/DK2563403T3/da active
- 2011-04-28 MY MYPI2012004682A patent/MY160510A/en unknown
- 2011-04-28 EP EP11719041.3A patent/EP2563403B1/en active Active
- 2011-04-28 JP JP2013506736A patent/JP2013525415A/ja active Pending
- 2011-04-28 GB GB1220669.4A patent/GB2492738B/en not_active Expired - Fee Related
- 2011-04-28 PH PH1/2012/502149A patent/PH12012502149A1/en unknown
- 2011-04-28 NZ NZ603938A patent/NZ603938A/xx not_active IP Right Cessation
- 2011-04-28 CA CA2796870A patent/CA2796870A1/en active Pending
- 2011-04-28 WO PCT/GB2011/000663 patent/WO2011135308A1/en not_active Ceased
- 2011-04-28 AP AP2012006574A patent/AP2012006574A0/xx unknown
- 2011-04-28 KR KR1020127031387A patent/KR20130055620A/ko not_active Ceased
- 2011-04-28 PE PE2012002103A patent/PE20130253A1/es not_active Application Discontinuation
-
2012
- 2012-10-21 IL IL222565A patent/IL222565A/en not_active IP Right Cessation
- 2012-10-29 CL CL2012003038A patent/CL2012003038A1/es unknown
- 2012-10-29 NI NI201200161A patent/NI201200161A/es unknown
- 2012-11-14 CR CR20120580A patent/CR20120580A/es unknown
- 2012-11-15 CO CO12207049A patent/CO6660500A2/es unknown
- 2012-11-28 EC ECSP12012315 patent/ECSP12012315A/es unknown
- 2012-11-28 ZA ZA2012/08988A patent/ZA201208988B/en unknown
-
2015
- 2015-02-05 JP JP2015021550A patent/JP2015110636A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130253A1 (es) | Factor viia conjugado para coagulacion de la sangre | |
| PE20130254A1 (es) | Factor viii conjugado para coagulacion de la sangre | |
| PE20120582A1 (es) | Conjugados de insulina cristalina | |
| ECSP109987A (es) | Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| CY1119269T1 (el) | Θεραπεια βλαβων που προκαλουνται απο ιους | |
| MA31953B1 (fr) | Nouveaux derives du thiophene. | |
| CY1118104T1 (el) | Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης | |
| AR076316A1 (es) | Composiciones para el cuidado de telas que comprenden polimeros de organosiloxano. | |
| CR11251A (es) | Depsipeptidos ciclicos y usos de los mismos | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| PE20200844A1 (es) | Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x | |
| MA32369B1 (fr) | Composes de benzene sulfonamide thiazole et oxazole | |
| BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
| CR10602A (es) | Cateter permanete con caracteristicas anticoagulantes. | |
| ECSP088221A (es) | Agonistas adrenoreceptores alfa2c | |
| UY32292A (es) | Agonistas de s1p1 y métodos de preparación y uso | |
| CO6990738A2 (es) | Agentes de reversion anticoagulante | |
| CL2009001804A1 (es) | Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas. | |
| CY1119274T1 (el) | Μια μεθοδος και συνθεση για την καταπολεμηση εκτοπαρασιτων | |
| PE20181069A1 (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| AR089068A1 (es) | Composiciones para el cuidado del cabello que contiene un polimero de aminosilicona | |
| UY29486A1 (es) | Compuestos utiles en terapia | |
| BRPI1003940B8 (pt) | Composição para cuidado de saúde compreendendo um tensoativo polimerizado de baixo dp e um espessante micelar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |